{"id":"placebo-to-mycophenolate-mofetil","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)"},{"rate":"20-30","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Tremor"},{"rate":"10-20","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), its active form. MPA preferentially inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it suppresses T and B cell proliferation while having minimal effects on other cell types, making it useful for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Mycophenolate mofetil is an immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), reducing proliferation of T and B lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:31.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients"},{"name":"Active lupus nephritis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT05538208","phase":"PHASE2","title":"The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-06-07","conditions":"Lupus Nephritis","enrollment":105},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04883619","phase":"PHASE2","title":"A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-15","conditions":"Lupus Nephritis","enrollment":""},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT02990286","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-01-20","conditions":"Lung Disease, Interstitial","enrollment":122},{"nctId":"NCT05201469","phase":"PHASE2","title":"VIBRANT: VIB4920 for Active Lupus Nephritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-16","conditions":"Lupus Nephritis","enrollment":74},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05306873","phase":"PHASE2","title":"Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-30","conditions":"Systemic Lupus Erythematosus","enrollment":12},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT05785065","phase":"PHASE2","title":"Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2024-08-29","conditions":"Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease","enrollment":35},{"nctId":"NCT04376827","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Lupus Nephritis","enrollment":33},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT05113004","phase":"PHASE2","title":"New Clinical End-points in Patients With Primary Sjögren's Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-20","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":300},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT06549231","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-15","conditions":"Interstitial Lung Disease With Systemic Sclerosis","enrollment":102},{"nctId":"NCT03221257","phase":"PHASE2","title":"Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate","status":"COMPLETED","sponsor":"Michael Roth","startDate":"2017-11-28","conditions":"Scleroderma, Systemic, Interstitial Lung Disease","enrollment":51},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT02028884","phase":"PHASE3","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-20","conditions":"Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)","enrollment":85},{"nctId":"NCT03917797","phase":"PHASE2","title":"Mesenchymal Stromal Cells (MSC´s) in Renal Lupus","status":"UNKNOWN","sponsor":"Universidad de los Andes, Chile","startDate":"2019-04-02","conditions":"Lupus Erythematosus, Systemic, Lupus Glomerulonephritis","enrollment":39},{"nctId":"NCT03943147","phase":"PHASE2","title":"An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2019-07-15","conditions":"Lupus Nephritis","enrollment":16},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT01670565","phase":"PHASE2","title":"Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2012-08","conditions":"Systemic Sclerosis","enrollment":20},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT03303989","phase":"PHASE2","title":"REduCing Immunogenicity to PegloticasE (RECIPE) Study","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-06-14","conditions":"Gout Chronic","enrollment":35},{"nctId":"NCT01085097","phase":"PHASE2","title":"A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-09-01","conditions":"Lupus Nephritis","enrollment":46},{"nctId":"NCT00021489","phase":"PHASE2","title":"Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02266888","phase":"PHASE2","title":"B Cell Induction in Pediatric Lung Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-22","conditions":"Lung Transplant","enrollment":45},{"nctId":"NCT02370693","phase":"PHASE2","title":"Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-03","conditions":"Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT01714817","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-22","conditions":"Lupus Nephritis","enrollment":695},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT02383589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Pemphigus Vulgaris","enrollment":135},{"nctId":"NCT00594932","phase":"PHASE1, PHASE2","title":"Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2006-11","conditions":"Systemic Lupus Erythematosus, Arthritis","enrollment":27},{"nctId":"NCT00539838","phase":"PHASE3","title":"A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-12-19","conditions":"Systemic Lupus Erythematosus","enrollment":33},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT04168944","phase":"PHASE2, PHASE3","title":"Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-11","conditions":"Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT02432339","phase":"PHASE1, PHASE2","title":"Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress","status":"UNKNOWN","sponsor":"Augusta University","startDate":"2014-04-22","conditions":"Psychological Stress, Hypertension, Renal","enrollment":50},{"nctId":"NCT02745145","phase":"PHASE2","title":"Abituzumab in SSc-ILD","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2016-05-31","conditions":"Systemic Sclerosis-associated Interstitial Lung Disease","enrollment":24},{"nctId":"NCT01399047","phase":"PHASE2","title":"Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-07","conditions":"Juvenile Neuronal Ceroid Lipofuscinosis","enrollment":19},{"nctId":"NCT02649504","phase":"PHASE3","title":"Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12-01","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT03580291","phase":"PHASE2","title":"Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)","status":"UNKNOWN","sponsor":"Lingyun Sun","startDate":"2018-08-01","conditions":"Lupus Nephritis","enrollment":230},{"nctId":"NCT02896205","phase":"PHASE3","title":"Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-10","conditions":"Systemic Sclerosis, Scleroderma, Interstitial Lung Disease","enrollment":41},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT02563782","phase":"PHASE2","title":"Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD","status":"WITHDRAWN","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2015-08-24","conditions":"Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT00883129","phase":"PHASE2","title":"Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)","status":"COMPLETED","sponsor":"Michael Roth","startDate":"2009-09","conditions":"Scleroderma, Interstitial Lung Disease","enrollment":142},{"nctId":"NCT01499355","phase":"PHASE2","title":"BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2012-07","conditions":"Lupus Nephritis","enrollment":276},{"nctId":"NCT00048165","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-08","conditions":"Heart Transplantation","enrollment":434},{"nctId":"NCT00573157","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2007-12","conditions":"Lupus Nephritis","enrollment":6},{"nctId":"NCT00318474","phase":"PHASE3","title":"Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2002-01","conditions":"IgA Nephropathy","enrollment":184},{"nctId":"NCT00617604","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"De Novo Kidney Transplantation","enrollment":218},{"nctId":"NCT00430677","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Systemic Lupus Erythematosus","enrollment":423},{"nctId":"NCT00282347","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01","conditions":"Lupus Nephritis","enrollment":144},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00089141","phase":"PHASE3","title":"Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)","status":"TERMINATED","sponsor":"Martin, Paul","startDate":"2004-05","conditions":"Cancer","enrollment":151},{"nctId":"NCT00658333","phase":"PHASE4","title":"A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00400400","phase":"PHASE4","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":400},{"nctId":"NCT00683930","phase":"PHASE3","title":"A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-05","conditions":"Pemphigus Vulgaris (PV)","enrollment":96},{"nctId":"NCT00451867","phase":"PHASE3","title":"A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2007-03","conditions":"Interstitial Cystitis, Painful Bladder Syndrome","enrollment":210},{"nctId":"NCT00683969","phase":"PHASE3","title":"A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":"Myasthenia Gravis, Generalized","enrollment":136},{"nctId":"NCT00408213","phase":"PHASE3","title":"A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Myasthenia Gravis Generalised","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":264,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to Mycophenolate mofetil","genericName":"Placebo to Mycophenolate mofetil","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil is an immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), reducing proliferation of T and B lymphocytes. Used for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Autoimmune conditions (off-label use in various settings).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}